Skip to main content

Trading Emissions Rights

Image result for EU
The European Union initiated its Emissions Trading Scheme in 2005. This was the first large-scale such trading scheme in the world. The idea was to reduce the greenhouse emissions of Europe’s industries in a market-rational manner, and to offer the rest of the world an example of how that is done.

The ETS is also known as the cap-and-trade system. That phrase suggests the good news/bad news split for markets. Bad news: there are regulatory caps on the total amount of specified gases that may be released. Good news: any particular installation can buy allowances from others to cover otherwise prohibited emissions. As a basic matter of economic theory, these allowances should be traded toward their highest and best use, ensuring that the system over all is more efficient than any command and control approach to the problem could be.

Does it work? And for whom?

The system has in fact drawn imitation, in both New Zealand and in Australia. In the U.S., California has its own cap-and-trade program.

The system seems to exist largely at the expense of electricity ratepayers. That feature of the system gives it the appearance of something that is not sustainable.  

At least two recent studies speak to this point. The Oxford Institute for Energy Studies has published a white paper that declares in its very title that “electricity markets are broken” and asks whether they can be fixed. It concludes flatly that “there is no possibility of a long-term self-sustaining low carbon market based on the mixture of sources envisaged by governments.”

Separately, the Manhattan Institute has posted an “issue brief” entitled: “What Happens to an Economy When Forced to Use Renewable Energy?” This brief, by Robert Bryce, a senior fellow, seems directly relevant to what really counts as socially responsible investing. After all, it is a priori reasonable that investing in a way that helps keep electrical rates reasonable is both wise and sustainable. 



Comments

  1. You may be eligible for a new solar program.
    Find out if you are qualified now!

    ReplyDelete
  2. eToro is the ultimate forex trading platform for new and established traders.

    ReplyDelete

Post a Comment

Popular posts from this blog

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Francesco Orsi

I thought briefly that I had found a contemporary philosopher whose views on ethics and meta-ethics checked all four key boxes. An ally all down the line.

The four, as regular readers of this blog may remember, are: cognitivism, intuitionism, consequentialism, pluralism. These represent the views that, respectively: some ethical judgments constitute knowledge; one important source for this knowledge consists of quasi-sensory non-inferential primary recognitions ("intuitions"); the right is logically dependent upon the good; and there exists an irreducible plurality of good.

Francesco Orsi seemed to believe all of these propositions. Here's his website and a link to one relevant paper:

https://sites.google.com/site/francescoorsi1/

https://jhaponline.org/jhap/article/view/3

What was better: Orsi is a young man. Born in 1980. A damned child! Has no memories of the age of disco!

So I emailed him asking if I was right that he believed all of those things. His answer: three out of …